Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study

Victoria Furer,Nizar Higazi,David Levartovsky,Gabi Shefer,Hila Nochomovitz,Ofir Elalouf,Orli Sharon ,Ira Litinsky,Ari Polachek,Adi Broyde,Daphna Paran,Tal Gazzit,Katya Meridor,Amir Haddad,Sharon Nevo,Roni Meidan,Joy Feld,Dana Rosenberg,Sara Pel,Fadi Kharouf,Michael Zisapel,Devy Zisman,Tali Eviatar,Hagit Peleg,Ilana Kaufman,Muna Elias,Jonathan Wollman,Adi Silberman,Ori Elkayam

doi:10.1136/annrheumdis-2021-220647

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study

Victoria Furer, Nizar Higazi + Show 27 more

Open Access

https://doi.org/10.1136/annrheumdis-2021-220647

Copy DOI

Journal: Annals of the Rheumatic Diseases	Publication Date: Jun 14, 2021
Citations: 529	License type: covid-19-tdm

Affiliation: Tel Aviv University, Carmel Medical Center, Tel Aviv Sourasky Medical Center, Hebrew University of Jerusalem, Hadassah Academic College, Technion – Israel Institute of Technology

#Autoimmune Inflammatory Rheumatic Diseases #Major Adverse Events In Patients + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

IntroductionVaccination represents a cornerstone in mastering the COVID-19 pandemic. Data on immunogenicity and safety of messenger RNA (mRNA) vaccines in patients with autoimmune inflammatory rheumatic diseases (AIIRD) are limited.MethodsA multicentre...

Full Text